Ankylosing Spondylitis Medication Clinical Trails Results Published
Ankylosing spondylitis is a chronical autoimmune disease, characterized by long-term inflammation of the joints of the spine. Although there is no cure for the disease, treatment and medication can significantly reduce symptoms and pain for patients.
The new monoclonal antibody-based pharmaceutical was developed by the BIOCAD company in cooperation with the researchers from the Pirogov Russian National Research Medical University. The action of the pharmaceutical is aimed at slowing down the immune inflammatory process.
The antibodies bind to the TRBV9 gene segment on the surface of the pathogenic T-lymphocytes responsible for triggering the autoinflammatory reaction. No analogue of the pharmaceutical currently exists in the world. The treatment affects the cause of the disease instead of only relieving the symptoms.
The pharmaceutical, which has received an international nonproprietary name "seniprutug", was being tested on 260 patients over the course of 36 weeks. The treatment was shown to reduce systemic inflammatory level, with improvements also observed in patients with active forms of the disease. During the clinical trial, the safety and acceptability of the pharmaceutical were also demonstrated.
Shortly after the results of the Phase II trials were published, the experts called the treatment a breakthrough. The developers have submitted the documents for the registration of the pharmaceutical.
Source: PharmMedProm
Ankylosing spondylitis is a chronical autoimmune disease, characterized by long-term inflammation of the joints of the spine. Although there is no cure for the disease, treatment and medication can significantly reduce symptoms and pain for patients.
The new monoclonal antibody-based pharmaceutical was developed by the BIOCAD company in cooperation with the researchers from the Pirogov Russian National Research Medical University. The action of the pharmaceutical is aimed at slowing down the immune inflammatory process.
The antibodies bind to the TRBV9 gene segment on the surface of the pathogenic T-lymphocytes responsible for triggering the autoinflammatory reaction. No analogue of the pharmaceutical currently exists in the world. The treatment affects the cause of the disease instead of only relieving the symptoms.
The pharmaceutical, which has received an international nonproprietary name "seniprutug", was being tested on 260 patients over the course of 36 weeks. The treatment was shown to reduce systemic inflammatory level, with improvements also observed in patients with active forms of the disease. During the clinical trial, the safety and acceptability of the pharmaceutical were also demonstrated.
Shortly after the results of the Phase II trials were published, the experts called the treatment a breakthrough. The developers have submitted the documents for the registration of the pharmaceutical.
Source: PharmMedProm